-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3101 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3101 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3101 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MER-3001 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MER-3001 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MER-3001 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
EnviRecover Energy-from-Waste facility
EnviRecover Energy-from-Waste facility is a biopower project located in England, United Kingdom. The project is owned by Mercia Waste Management. The project came online in 2017. Empower your strategies with our EnviRecover Energy-from-Waste facility report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
Mercia RE – Sutton Coldfield Mixed-Use Complex Redevelopment – City and Borough of Birmingham
Equip yourself with the essential tools needed to make informed and profitable decisions with our Mercia RE - Sutton Coldfield Mixed-Use Complex Redevelopment - City and Borough of Birmingham report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Company Profile
Mercia Asset Management PLC – Company Profile
Mercia Asset Management PLC (Mercia), formerly Mercia Technologies PLC, is a specialist asset manager, which focuses on high-growth SMEs in the UK. Through direct investments and managed funds, it provides capital across four asset classes such as venture, private equity, debt, and balance sheet. The company invests in various sectors, including digital and digital entertainment, life sciences and biosciences, software and internet, electronics, materials, manufacturing, and engineering. Its investment portfolio includes Abbey Telecomm, Abingdon Health, Aceleron, Blue Prism, Celentyx, Collabco,...
Add to Basket -
Sector Analysis
Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Report Overview Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. Â Influenza infection is normally self-limiting. Symptoms generally last for one to two weeks, but most people infected with influenza do not need or seek medical treatment. The Seasonal Influenza Therapeutics (SIT) marketed and pipeline drugs market research report provides a data-driven overview...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MER-3101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MER-3101 Drug Details MER-3101 is under development for the prevention and treatment of type...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MER-4101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MER-4101 Drug Details MER-4101 is under development for the prevention of seasonal influenza. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MER-3001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MER-3001 Drug Details MER-3001 is under development for the treatment of Type I Diabetes...